Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Non-Current Assets (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Non-Current Assets for 11 consecutive years, with $10000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Non-Current Assets fell 96.96% year-over-year to $10000.0, compared with a TTM value of $10000.0 through Dec 2025, down 98.53%, and an annual FY2024 reading of $10000.0, down 96.98% over the prior year.
  • Non-Current Assets was $10000.0 for Q1 2025 at Spyre Therapeutics, roughly flat from $10000.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $12.6 million in Q2 2021 and bottomed at $10000.0 in Q3 2024.
  • Average Non-Current Assets over 5 years is $5.9 million, with a median of $8.1 million recorded in 2023.
  • The sharpest move saw Non-Current Assets grew 16.03% in 2021, then plummeted 99.24% in 2024.
  • Year by year, Non-Current Assets stood at $11.0 million in 2021, then fell by 19.47% to $8.9 million in 2022, then plummeted by 96.28% to $331000.0 in 2023, then crashed by 96.98% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
  • Business Quant data shows Non-Current Assets for SYRE at $10000.0 in Q1 2025, $10000.0 in Q4 2024, and $10000.0 in Q3 2024.